Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 9, Issue 6, Pages -
Publisher
Springer Nature
Online
2018-06-07
DOI
10.1038/s41419-018-0717-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study
- (2017) Tanya I. Coulter et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities
- (2017) Nicole J. Flynn et al. Targeted Oncology
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- Macrophage PI3K Drives Pancreatic Ductal Adenocarcinoma Progression
- (2016) M. M. Kaneda et al. Cancer Discovery
- Focal adhesion kinase phosphorylates the phosphatase and tensin homolog deleted on chromosome 10 under the control of p110δ phosphoinositide-3 kinase
- (2015) Niki Tzenaki et al. FASEB JOURNAL
- The interaction of anticancer therapies with tumor-associated macrophages
- (2015) Alberto Mantovani et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Molecules in medicine mini-review: isoforms of PI3K in biology and disease
- (2015) Bart Vanhaesebroeck et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Macrophages and cancer: from mechanisms to therapeutic implications
- (2015) Renato Ostuni et al. TRENDS IN IMMUNOLOGY
- Focus on PTEN regulation
- (2015) Miriam Bermúdez Brito Frontiers in Oncology
- PI3Kδ Inhibition Hits a Sensitive Spot in B Cell Malignancies
- (2014) Bart Vanhaesebroeck et al. CANCER CELL
- Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
- (2014) Carola H. Ries et al. CANCER CELL
- Arginase activity in alternatively activated macrophages protects PI3Kp110δ deficient mice from dextran sodium sulfate induced intestinal inflammation
- (2014) Shelley B. Weisser et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- PI3K and cancer: lessons, challenges and opportunities
- (2014) David A. Fruman et al. NATURE REVIEWS DRUG DISCOVERY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
- (2013) Giovanni Germano et al. CANCER CELL
- Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency
- (2013) Carrie L Lucas et al. NATURE IMMUNOLOGY
- Genetic heterogeneity of diffuse large B-cell lymphoma
- (2013) Jenny Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phosphoinositide 3-Kinase Gene Mutation Predisposes to Respiratory Infection and Airway Damage
- (2013) I. Angulo et al. SCIENCE
- High levels of p110δ PI3K expression in solid tumor cells suppress PTEN activity, generating cellular sensitivity to p110δ inhibitors through PTEN activation
- (2012) Niki Tzenaki et al. FASEB JOURNAL
- The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
- (2011) J. Hoellenriegel et al. BLOOD
- The prognostic significance of B lymphocytes in invasive carcinoma of the breast
- (2011) S. M. A. Mahmoud et al. BREAST CANCER RESEARCH AND TREATMENT
- Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo
- (2011) Kazunori Anzai et al. CANCER SCIENCE
- The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
- (2011) H. Tanaka et al. CLINICAL CANCER RESEARCH
- CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies
- (2011) Jorge J Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Image Analysis Tools for Evaluation of Microscopic Views of Immunohistochemically Stained Specimen in Medical Research–a Review
- (2011) Keerthana Prasad et al. JOURNAL OF MEDICAL SYSTEMS
- Macrophages limit chemotherapy
- (2011) Michele De Palma et al. NATURE
- PI3K Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic
- (2011) D. A. Fruman et al. Cancer Discovery
- PI3K p110 regulates T-cell cytokine production during primary and secondary immune responses in mice and humans
- (2010) D. R. Soond et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- (2010) S. E. M. Herman et al. BLOOD
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors
- (2010) K. A. Edgar et al. CANCER RESEARCH
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- The emerging mechanisms of isoform-specific PI3K signalling
- (2010) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PTEN and the PI3-Kinase Pathway in Cancer
- (2008) Nader Chalhoub et al. Annual Review of Pathology-Mechanisms of Disease
- A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
- (2008) Neil E. Torbett et al. BIOCHEMICAL JOURNAL
- Multiple immunofluorescence labelling of formalin-fixed paraffin-embedded (FFPE) tissue
- (2008) David Robertson et al. BMC CELL BIOLOGY
- Membrane-type 1 Matrix Metalloproteinase Regulates Macrophage-dependent Elastolytic Activity and Aneurysm Formationin Vivo
- (2008) Wanfen Xiong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
- (2008) Shidong Jia et al. NATURE
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers
- (2008) Q Zhu et al. ONCOGENE
- PI3K pathway alterations in cancer: variations on a theme
- (2008) T L Yuan et al. ONCOGENE
- PTEN-deficient cancers depend on PIK3CB
- (2008) S. Wee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- Phosphoinositide 3-Kinase p110 Activity: Key Role in Metabolism and Mammary Gland Cancer but Not Development
- (2008) E. Ciraolo et al. Science Signaling
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started